Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Increase in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 31st, there was short interest totalling 289,700 shares, a growth of 35.6% from the May 15th total of 213,600 shares. Based on an average trading volume of 196,400 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.8% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Immix Biopharma in a report on Wednesday, June 4th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Immix Biopharma stock. Jane Street Group LLC bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned about 0.06% of Immix Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 11.26% of the company's stock.

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX traded down $0.15 during mid-day trading on Friday, hitting $2.24. 139,384 shares of the stock were exchanged, compared to its average volume of 155,648. Immix Biopharma has a twelve month low of $1.26 and a twelve month high of $3.00. The stock's fifty day simple moving average is $2.06 and its two-hundred day simple moving average is $1.98. The company has a market cap of $62.44 million, a P/E ratio of -3.20 and a beta of 0.31.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. As a group, equities research analysts predict that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.